Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDE™
Avidity to host Volume 9 of investor and analyst event series via webcast June 12, 2024, at 8:00 a.m. ET
SAN DIEGO, May 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and one poster presentation at the 31st Annual FSHD Society International Research Congress, being held June 13-14, 2024, in Denver, Colorado.
Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE™ trial investigator, will present preliminary data from the Phase 1/2 FORTITUDE™ clinical trial of AOC 1020 in people living with facioscapulohumeral muscular dystrophy (FSHD).